Goodwin Guides the Underwriters on Taysha’s $230 Million Underwritten Public Offering

The Life Sciences team guided joint book-running managers Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor, and lead manager, Baird, on the underwritten public offering for Taysha Gene Therapies, Inc. (“Taysha”). The offering included 38,333,334 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, inclusive of the underwriters’ option to purchase an additional 5,000,000 shares of common stock at the public offering price, in each case before underwriting discounts and commissions. All of the securities were offered by Taysha. The gross proceeds from the offering to Taysha were approximately $230 million before deducting underwriting discounts, commissions, and other offering expenses.

Taysha is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers.

The Goodwin team was led by Ben Marsh, Janet Hsueh, Lauren Zhang, Haylee Brown, and Hayden Hunt, and included Steve Tjoe, Olivia Uitto, Heath Ingram, and Maggie Wong.

For more information on the deal, please read the pricing press release.